Table 1

Baseline characteristics of the study population

COVID-19
(n=1086)
Control subjects
(n=10 860)
Age, median (IQR), years62.0 (52.0–70.0)62.0 (52.0–70.0)
Sex
 Male, number (%)813 (74.9)8130 (74.9)
Sociodemographics number (%)
Education (years)
 ≤9280 (26.8)2144 (20.1)
 10–12466 (44.6)4805 (45.1)
 ≥12300 (28.7)3712 (34.8)
Marital status
 Widow41 (3.8)405 (3.7)
 Married632 (58.2)5641 (51.9)
 Single218 (20.1)2802 (25.8)
 Separated195 (18.0)2012 (18.5)
Region of birth
 EU 15* and/or Nordics596 (55.1)8411 (77.5)
Medical history number (%)
 Type 1 diabetes9 (0.8)39 (0.4)
 Type 2 diabetes276 (25.4)1255 (11.6)
 Obesity99 (9.1)328 (3.0)
 Hypertension547 (50.4)4258 (39.2)
 Hyperlipidaemia292 (33.0)2100 (28.6)
 Chronic kidney disease40 (3.7)146 (1.3)
 Cardiovascular disease105 (9.7)992 (9.1)
 Myocardial infarction55 (5.1)559 (5.1)
 Ischaemic stroke29 (2.7)274 (2.5)
 Peripheral artery disease24 (2.2)249 (2.3)
 Heart failure40 (3.7)329 (3.0)
 Atrial fibrillation65 (6.0)589 (5.4)
 Deep vein thrombosis40 (3.7)208 (1.9)
 Pulmonary embolism13 (1.2)103 (0.9)
 Chronic obstructive pulmonary disease32 (2.9)237 (2.2)
 Asthma100 (9.2)376 (3.5)
 Malignancy158 (14.5)1740 (16.0)
 Rheumatoid arthritis17 (1.6)96 (0.9)
 Systemic inflammatory disease33 (3.0)129 (1.2)
 Inflammatory bowel disease17 (1.6)159 (1.5)
  • Characteristics of patients with COVID-19 requiring mechanical ventilation and control subjects.

  • *EU 15 comprises of Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Netherlands, Portugal, Spain, Sweden, UK. The Nordic countries include Denmark, Finland, Iceland, Norway and Sweden.